Aileron Historical Financial Ratios
| ALRN Stock | USD 2.86 0.12 4.38% |
Aileron Therapeutics is presently reporting on over 105 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.14 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Aileron Therapeutics financial condition quickly.
Aileron |
About Aileron Financial Ratios Analysis
Aileron TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aileron Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aileron financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aileron Therapeutics history.
Aileron Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Aileron Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Aileron Therapeutics sales, a figure that is much harder to manipulate than other Aileron Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Net Profit Margin
The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.Most ratios from Aileron Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aileron Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.At this time, Aileron Therapeutics' Current Ratio is very stable compared to the past year. As of the 30th of November 2024, Enterprise Value Over EBITDA is likely to grow to 0.22, while Book Value Per Share is likely to drop 20.31.
| 2023 | 2024 (projected) | Interest Debt Per Share | 0.0104 | 0.009916 | Revenue Per Share | 1.1K | 941.06 |
Aileron Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Aileron Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aileron Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 0.88 | 2.98 | 1.14 | 0.58 | 2.04 | 2.14 | |
| Book Value Per Share | 13.08 | 6.98 | 9.89 | 4.1 | 21.37 | 20.31 | |
| Free Cash Flow Yield | (1.89) | (0.56) | (0.48) | (2.31) | (1.41) | (1.48) | |
| Operating Cash Flow Per Share | (21.58) | (11.75) | (5.35) | (5.48) | (4.31) | (4.52) | |
| Capex To Depreciation | 20.29 | 0.97 | 0.0307 | 1.3 | 1.17 | 1.11 | |
| Pb Ratio | 0.88 | 2.98 | 1.14 | 0.58 | 2.04 | 2.14 | |
| Free Cash Flow Per Share | (21.7) | (11.75) | (5.38) | (5.48) | (4.31) | (4.52) | |
| Roic | (1.78) | (1.68) | (0.59) | (1.46) | (2.35) | (2.23) | |
| Net Income Per Share | (23.46) | (12.52) | (5.8) | (5.95) | (3.42) | (3.59) | |
| Payables Turnover | 0.0594 | 0.13 | 0.11 | 0.1 | 0.0983 | 0.095 | |
| Cash Per Share | 14.9 | 7.92 | 10.34 | 4.68 | 3.76 | 3.58 | |
| Pocfratio | (0.53) | (1.77) | (2.1) | (0.43) | (0.71) | (0.74) | |
| Capex To Operating Cash Flow | (0.16) | (0.005704) | (2.44E-4) | (0.006609) | (0.007601) | (0.007981) | |
| Pfcf Ratio | (0.53) | (1.77) | (2.09) | (0.43) | (0.71) | (0.74) | |
| Days Payables Outstanding | 2.9K | 3.4K | 3.6K | 3.7K | 3.3K | 2.1K | |
| Ev To Operating Cash Flow | (0.52) | (1.45) | (1.96) | (0.23) | 0.16 | 0.17 | |
| Pe Ratio | (0.49) | (1.66) | (1.94) | (0.4) | (0.89) | (0.85) | |
| Return On Tangible Assets | (1.0) | (1.34) | (0.53) | (1.23) | (0.77) | (0.81) | |
| Ev To Free Cash Flow | (0.52) | (1.45) | (1.95) | (0.23) | 0.16 | 0.17 | |
| Earnings Yield | (2.05) | (0.6) | (0.52) | (2.51) | (1.12) | (1.18) | |
| Net Debt To E B I T D A | 0.009362 | 0.33 | 0.13 | 0.19 | 1.11 | 1.16 | |
| Current Ratio | 3.35 | 4.12 | 10.69 | 6.46 | 4.17 | 4.49 | |
| Tangible Book Value Per Share | 14.89 | 6.98 | 9.89 | 4.1 | 2.78 | 2.64 | |
| Graham Number | 83.1 | 44.32 | 35.93 | 23.44 | 10.74 | 10.2 | |
| Shareholders Equity Per Share | 13.08 | 6.98 | 9.89 | 4.1 | 1.5 | 1.42 | |
| Capex Per Share | 6.0 | 0.12 | 0.002868 | 0.0354 | 0.0407 | 0.0386 | |
| Graham Net Net | 6.4 | 5.52 | 9.31 | 3.93 | 2.09 | 1.98 | |
| Enterprise Value Over E B I T D A | (0.46) | (1.46) | (1.76) | (0.2) | 0.21 | 0.22 | |
| Price Earnings Ratio | (0.49) | (1.66) | (1.94) | (0.4) | (0.89) | (0.85) | |
| Price Book Value Ratio | 0.88 | 2.98 | 1.14 | 0.58 | 2.04 | 2.14 | |
| Price Earnings To Growth Ratio | 0.0108 | 0.0356 | 0.0362 | (0.15) | 0.021 | 0.022 | |
| Days Of Payables Outstanding | 2.9K | 3.4K | 3.6K | 3.7K | 3.3K | 2.1K | |
| Price To Operating Cash Flows Ratio | (0.53) | (1.77) | (2.1) | (0.43) | (0.71) | (0.74) | |
| Price To Free Cash Flows Ratio | (0.53) | (1.77) | (2.09) | (0.43) | (0.71) | (0.74) |
Pair Trading with Aileron Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aileron Stock
Moving against Aileron Stock
The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Return On Assets (0.26) | Return On Equity (0.44) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.